Results 251 to 260 of about 291,785 (296)
Some of the next articles are maybe not open access.
Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo +2 more
openaire +2 more sources
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo +2 more
openaire +2 more sources
Checkpoint blockade: the end of the beginning
Nature Reviews Immunology, 2021The early 2000s saw the first trials of checkpoint inhibitors in humans. Here, Jedd Wolchok discusses the first clinical results.
openaire +2 more sources
Adding to the checkpoint blockade armamentarium
Nature Medicine, 2019Antitumor immunity can be enhanced by blocking NKG2A, an inhibitory receptor expressed on natural killer and T cells.
Matthew D. Hellmann, Alexandra Snyder
openaire +2 more sources
Masterful Antibodies: Checkpoint Blockade
Cancer Immunology Research, 2017Abstract Cancer therapeutics that target the immune system rather than the cancer cell itself are becoming standard of care in a growing number of different malignancies. Although cancer immunotherapy is not a new concept, the potential importance of this class of drugs was probably not fully appreciated as recently as a decade ago when ...
Nils, Lonberg, Alan J, Korman
openaire +2 more sources
Immune Checkpoint Blockade in Malignant Mesothelioma
Seminars in Oncology, 2015Malignant mesothelioma (MM) is a highly aggressive malignancy with a very dismal prognosis. Current treatment for unresectable MM is largely unsatisfactory; therefore, new therapeutic approaches are eagerly awaited. A better understanding of the complex mechanisms of immune escape operated by neoplastic cells and the ability to unleash an efficient ...
Calabro' L, Maio M.
openaire +3 more sources
The future of microfluidics in immune checkpoint blockade
Cancer Gene Therapy, 2020Recent advances in microfluidic techniques have enabled researchers to study sensitivities to immune checkpoint therapy, to determine patients' response to particular antibody treatment. Utilization of this technology is helpful in antibody discovery and in the design of personalized medicine.
Jonathan Briones +5 more
openaire +2 more sources
Combined Immune Checkpoint Blockade
Seminars in Oncology, 2015There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the ...
openaire +2 more sources
Checkpoint blockade in combination with cancer vaccines
Vaccine, 2015Checkpoint blockade, prevention of inhibitory signaling that limits activation or function of tumor antigen-specific T cells responses, is revolutionizing the treatment of many poor prognosis malignancies. Indeed monoclonal antibodies that modulate signaling through the inhibitory molecules CTLA-4 and PD-1 are now clinically available; however, many ...
Michael A, Morse, H Kim, Lyerly
openaire +2 more sources
Pseudoprogression and hyperprogression after checkpoint blockade
International Immunopharmacology, 2018Immune checkpoint inhibitors appear to be one of the most promising immunotherapies with significant clinical benefits and durable responses in multiple tumor types. A heterogeneity of responses appears in patients receiving checkpoint blockade, including pseudoprogression where the tumor burden or number of tumor lesions increases initially before ...
Qiaohong Wang, Jingze Gao, Xia Wu
openaire +2 more sources
Mechanisms of Resistance to Checkpoint Blockade Therapy
2020Immune checkpoint blockades (ICBs), as a major breakthrough in cancer immunotherapy, target CTLA-4 and the PD-1/PD-L1 axis and reinvigorate anti-tumor activities by disrupting co-inhibitory T-cell signaling. With unprecedented performance in clinical trials, ICBs have been approved by FDA for the treatment of malignancies such as melanoma, non-small ...
Hubing, Shi, Jiang, Lan, Jiqiao, Yang
openaire +2 more sources